Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor

Related articles

1. A Suite of Biochemical and Cell-Based Assays for the Characterization of KRAS Inhibitors and Degraders

   This article has 13 authors:

   1. Medhanie Kidane
   2. Rene M. Hoffman
   3. Jennifer K. Wolfe-Demarco
   4. Ting-Yu Huang
   5. Chi-Ling Teng
   6. Luis M. Gonzalez Lira
   7. Jennifer Lin-Jones
   8. Gabriel Pallares
   9. Jane E. Lamerdin
   10. Nicole B. Servant
   11. Chun-Yao Lee
   12. Chao-Tsung Yang
   13. Jean A. Bernatchez

2. Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma

   This article has 13 authors:

   1. Andrew Goetz
   2. Frances Shanahan
   3. Logan Brooks
   4. Eva Lin
   5. Rana Mroue
   6. Darlene Dela Cruz
   7. Thomas Hunsaker
   8. Bartosz Czech
   9. Purushottam Dixit
   10. Udi Segal
   11. Scott Martin
   12. Scott A. Foster
   13. Luca Gerosa

3. Discovery of the first-efficacious A _2A R negative allosteric modulators for high adenosine cancer immunotherapies

   This article has 11 authors:

   1. Margot Boujut
   2. Margaux Héritier
   3. Aurélie Gouiller
   4. Camille Süess
   5. Alessandro Scapozza
   6. Thibaut De Smedt
   7. Maxime Guibert
   8. Sébastien Tardy
   9. Hesham Hamed
   10. David Pejoski
   11. Leonardo Scapozza